Ethyl 1-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,5-a]pyridine-3-carboxylate | 1196879-64-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: Ethyl 1-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,5-a]pyridine-3-carboxylate
• CAS: 1196879-64-7
• 化学式: C₁₆H₁₉F₂N₃O₂
• 分子量: 323.343
• InChiKey: BGFHWVVCIPVTLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Ethyl 1-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,5-a]pyridine-3-carboxylate 在 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-((4,4-difluoropiperidin-1-yl)methyl)-N-(6-(trifluoromethyl)pyridin-2-yl)imidazo[1,5-a]pyridine-3-carboxamide
  参考文献：
  名称：

  Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy

  摘要：

  A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a highly selective CB2 agonist in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist exhibited significant analgesic effects. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.082
• 作为产物：
  描述：

  咪唑并[1,5-a]吡啶-3-羧酸乙酯 在 三乙酰氧基硼氢化钠 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 Ethyl 1-[(4,4-difluoropiperidin-1-yl)methyl]imidazo[1,5-a]pyridine-3-carboxylate
  参考文献：
  名称：

  Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy

  摘要：

  A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a highly selective CB2 agonist in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist exhibited significant analgesic effects. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.082

文献信息

• CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN
  申请人：Wu Zhicai

  公开号：US20120004222A1

  公开（公告）日：2012-01-05

  The present invention relates to compounds represented by Formula (I) and Formula (II): or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.

  本发明涉及由公式（I）和公式（II）表示的化合物或其药学上可接受的盐。本发明还提供包含这些化合物的药物组合物。此外，本发明还提供用于治疗和预防疼痛、呼吸和非呼吸性疾病的方法。
• [EN] CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN<br/>[FR] LIGANDS DE RÉCEPTEUR CB2 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：MERCK & CO INC

  公开号：WO2009025785A2

  公开（公告）日：2009-02-26

  The present invention relates to compounds represented by Formula (I) and Formula (II): or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.